ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an incurable hematological malignancy. Although proteasome inhibitors and immunomodulators have significantly improved patient outcomes, some patients respond poorly to treatment and almost all patients will relapse. Mechanisms of proteasome inhibitor resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jifeng, Sun, Yifeng, Xu, Jiadai, Xu, Tianhong, Xu, Zhao, Liu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541163/
https://www.ncbi.nlm.nih.gov/pubmed/32780537
http://dx.doi.org/10.1002/cam4.3347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541163/
https://www.ncbi.nlm.nih.gov/pubmed/32780537
http://dx.doi.org/10.1002/cam4.3347

Ejemplares similares